Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

– September 1, 2010

September 1, 2010

View Archives Issues

  • Breast Cancer in a Pregnant Woman

    A 31-year-old g1p0 caucasian woman in the seventh month of pregnancy is referred for management of her T2N0Mx "triple-negative" breast cancer.
  • Treatment of Primary Amyloidosis (AL)

    There are several forms of amyloidosis, each with distinct patterns of protein deposition and resulting clinical presentations.
  • Hepatitis B After Rituximab in NHL

    Hepatitis B virus (HBV) reactivation after rituximab or other immune suppressive therapies may lead to serious adverse outcomes. The authors retrospectively reviewed HBV serology of CD20 positive B-cell lymphoma without active HBV (i.e., negative HBsAg) before and after rituximab. Of the 230 tested, 56 (24%) were anti-HBc positive; the five cases of HBV reactivation all occurred in these 56 patients. Moreover, four of the five were anti-HBs negative (a.k.a, isolated anti-HBc). All received entacavir with the only HBV complication of transaminitis. None of the anti-HBc negative patients reactivated. Isolated anti-HBc, particularly lacking anti-HBs, may be at heightened risk of HBV reactivation after rituximab.
  • Clinical Briefs in Primary Care Supplement

  • Pharmacology Watch

    Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.